Background: HIV type-1 (HIV-1) drug resistance testing is rarely available in resource-limited settings because of high costs and stringent requirements for storage and transport of plasma. Dried blood spots (DBS) can be a convenient alternative to plasma, but the use of DBS needs validation under field conditions. We assessed the performance of DBS in genotypic resistance testing of patients who failed first-line antiretroviral therapy (ART) in rural Tanzania. Methods: A total of 36 ART-experienced patients with viral loads >1,000 copies/ml (median 15,180 copies/ml [range 1,350-3,683,000]) and with various HIV-1 subtypes were selected for resistance testing. DBS were stored with desiccant at ambient temperature for a median of 29 days (range 8-89). Samples were amplified using an in-house reverse transcriptase-nested PCR method and sequenced using the ViroSeq™ assay (Abbott Molecular, Des Plaines, IL, USA). DBS-derived genotypes were compared with genotypes from plasma. Results: Overall, 34 of 36 (94%) DBS specimens were successfully genotyped. In the protease region, of 142 polymorphisms found in plasma, 132 (93%) were also detected in DBS. In the reverse transcriptase region, of 57 clinically relevant mutations present in plasma, 51 (89%) were also detected in DBS. A total of 30 of 34 (88%) patients had identical resistance profiles to antiretroviral drugs in plasma and DBS. Conclusions: Genotyping was successful in the vast majority of DBS specimens stored at ambient temperature for up to 3 months, and there was high concordance between mutations found in DBS and plasma. Our study suggests that DBS can be a feasible and reliable tool to monitor HIV-1 drug resistance in patients on ART in resource-limited settings.
Introduction
Consequently, patients who fail treatment in such settings risk switching to ineffective, yet expensive and complex, second-line regimens [6, 7] .
Dried blood spots (DBS) can be a convenient alternative to plasma, and have been used for >40 years to screen for metabolic disorders in neonates [8] . Packed in zip-lock plastic bags with desiccant, DBS can be stored and shipped at ambient temperature, thus avoiding the need for cold chain and speedy transport to the laboratory [9, 10] . The use of DBS, therefore, can simplify sampling and reduce transport costs, making it a particularly suitable tool in remote resource-limited settings. Recently, several studies have found that HIV-1 drug resistance testing on DBS can be efficient and reliable [11] [12] [13] [14] [15] [16] [17] ; however, these studies were all carried out under standardized conditions in modern laboratories in high-income countries, and might not reflect reallife application in resource-limited settings. Therefore, we aimed to assess the performance of DBS in drug resistance monitoring in a routine ART programme in rural Tanzania. If proven reliable, this method could markedly improve access to drug resistance testing for HIV-1-infected individuals in resource-limited settings.
Methods

Study setting and participants
Haydom Lutheran Hospital is located in rural northern Tanzania, and was one of the first centres in the country to offer ART. Since 2003, ART has been provided free of charge to all eligible HIV-infected patients, in accordance with the World Health Organization (WHO) guidelines [18] [19] [20] . The standard first-line regimen in Tanzania comprises stavudine or zidovudine, with lamivudine, and either nevirapine or efavirenz. A fixed-dose combination of stavudine, lamivudine and nevirapine is preferred, whenever possible.
From November 2007 through June 2008, a crosssectional virological survey was carried out among patients who started ART ≥6 months before. Results from this survey have been published previously [21] . Patients with a plasma HIV-1 RNA viral load >1,000 copies/ml were selected for genotypic resistance testing, and DBS specimens were obtained in parallel with plasma for comparison. All patients gave written consent to participate in the study, and the study was approved by the National Institute for Medical Research (Tanzania), and the Regional Committee for Medical Research Ethics (Norway).
Plasma genotypic resistance testing
Whole blood was collected in plasma preparation tubes (PPTs; Becton Dickinson, Franklin Lakes, NJ, USA) by venous puncture and centrifuged within 3 h of collection. The resulting plasma was transferred into sterile plastic tubes and stored at -20°C for a median of 19.5 days (range 2-129), before being transported to the reference laboratory at Oslo University Hospital (Oslo, Norway).
RNA was isolated from 500-1,000 µl plasma using the ViroSeq™ HIV-1 Sample Preparation Module in ViroSeq™ HIV-1 Genotyping System version 2.0 (Abbott Molecular, Des Plaines, IL, USA), according to the manufacturer's instructions. Reverse transcriptase (RT)-nested PCR of the HIV-1 pol region was performed as described by Nyombi et al. [22] , using primer pair P2071 (HXB2 position 2071-2093) and P3709 (HXB2 position 3709-3686) for the RT-PCR and primer pair P2073G (HXB2 position 2073-2094) and P3681 (HXB2 position 3681-3705) for the secondary PCR.
Sequence analyses of the 1.6 kb pol fragment was performed using the ViroSeq™ HIV-1 Sequencing Module (Abbott Molecular) and the ABI Prism 3130xl Genetic Analyser (Applied Biosystems Inc., Foster City, CA, USA). The sequence, comprising amino acids 1-99 of the protease and 1-335 of the RT gene, was analysed and edited by ViroSeq™ HIV-1 Genotyping System Software version 2.6 (Abbott Molecular). HIV-1 subtypes and resistance profiles to antiretroviral drugs were interpreted according to the Stanford University HIV Drug Resistance Database. A total of 3 samples with inconclusive subtypes were reinterpreted according to the Los Alamos HIV Sequence Database. Only drug resistance mutations listed in the December 2009 update from the International AIDS Society were considered in the present study [23] .
Preparation and storage of dried blood spots DBS were prepared in parallel with plasma from the same blood samples. Whole blood from a PPT was spotted onto a Whatman 903 filter paper card (Whatman plc, Maidstone, UK) to completely fill the circles. The cards were then left to air-dry overnight, and were stored in zip-lock plastic dispensing bags (purchased locally) with a silica desiccant (Elcon-Broker AS, Holmestrand, Norway). The DBS cards were stored and shipped under tropical conditions (temperature range 24-28°C) for a median of 29 days (range 8-89). After arrival at the reference laboratory (Oslo University Hospital), samples were kept at -70°C until processing 1-8 months later. Humidity indicators were not used, but none of the DBS displayed signs of humidity on visual inspection.
Dried blood spot genotypic resistance testing
Total nucleic acids were extracted from two circles of dried blood, each of which holds 75-80 µl of whole blood [24] , using the NucliSENS ® silica-based Boom extraction method (bioMérieux, Inc., Durham, NC, USA) with some modifications for DBS processing [13, 25] . Briefly, the spots were cut with scissors, placed in 9 ml of NucliSENS ® lysis buffer and incubated for 2 h under gentle rotation at room temperature. The supernatant was clarified by centrifugation at 250×g for 5 min and then transferred to a clean 15 ml conical tube, into which 100 µl of silica was added to isolate nucleic acids, following the manufacturer's instructions. Finally, the silica was resuspended in 50 µl elution buffer, and 5 and 10 µl supernatant was directly added to the RT-PCR mix [22] . Further processing followed the same protocol as described above for plasma.
Statistical analyses
Results obtained with DBS were compared with those obtained with use of a standard plasma assay. Comparisons were made with regard to amplification success, detection of clinically relevant mutations and nucleotide similarity. Logistic regression was used to study factors associated with amplification failure. Data were analysed using SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL, USA), with the exception of 95% confidence intervals for proportions, which were calculated with NCSS version 2007 (NCSS, Kaysville, UT, USA). All tests were two-sided and the level of significance was set at P<0.05.
Results
Patient characteristics
A total of 36 ART-experienced individuals with a plasma viral load >1,000 copies/ml and a plasmaderived genotypic resistance result were included in this study. One patient was excluded because amplification from plasma failed.
Among the study participants, the median age was 30 years (range 2-68), and 27 (75%) patients were women. Median time since ART initiation was 27 months (range 9-49); however, at the time of the survey, 11 of 36 patients had chosen to discontinue treatment. Median plasma viral load was 15,180 copies/ml (range 1,350-3,683,000). Plasma HIV-1 subtypes were A (n=11), C (n=10), D (n=12) and CRF01_ AE (n=3).
Amplification rates from dried blood spots HIV-1 pol was successfully amplified in 34 of 36 (94%) DBS specimens (Table 1 ). In total, 3 of these 34 failed on the first attempt, but succeeded on a second attempt when three circles of dried blood were used. The two DBS specimens that could not be amplified on repeated testing both had low-level viraemia: 1,432 copies/ml (subtype CRF01_AE) and 2,621 copies/ml (subtype A). Neither of these two had been subjected to excessive storage (22 and 27 days, respectively, versus a median of 29 days for DBS specimens successfully genotyped); hence, DBS storage was not significantly associated with amplification failure (P=0.47).
Comparison of HIV type-1 drug-resistant mutations in plasma and dried blood spots
A total of 34 patients with a genotype from both plasma and DBS were compared. In the protease region, 142 mutations were detected in plasma, of which 132 (93%) were also found in DBS. Five protease mutations were detected in DBS only, all of which were amino acid mixtures with the wild-type strain: L33LI (patient 1), K20KR (patient 6), V32VI and L33LI (patient 9) and I64IV (patient 24). All plasma-derived protease mutations were minor mutations or polymorphisms classically associated with natural divergence of HIV-1 non-B subtypes, and none of the patients harboured resistance to protease inhibitors. In the RT region, however, 57 clinically significant mutations were found in plasma, of which 51 (89%) were also detected in DBS (Table 2 ). In total, 4 of the 6 RT mutations that were missed in DBS were from patients with early treatment failure (viral load ≤3,000 copies/ml). Two RT mutations were detected in DBS only, but both were amino acid mixtures in the 184 position with the same clinical interpretation: M184IMV in DBS and M184V in plasma (patients 15 and 18). The RT mutations present in plasma but absent in DBS from patient 11 (L210W), patient 16 (K103N and M184V), patient 21 (G190A) and patient 22 (M184I) had significant effects on drug resistance, whereas in patient 3 the presence of V108I did not modify the resistance profile significantly. Thus, 30 of 34 (88%) patients had identical resistance profiles to antiretroviral drugs in plasma and DBS, according to the Stanford interpretation. Nucleotide similarity between plasma and dried blood spots
The whole sequence of 1,302 bases was compared between plasma and DBS, with mixed bases being classified as different. Among 34 plasma/DBS pairs, the mean ±sd nucleotide similarity was 98.1% ±0.87, ranging from 96.2-99.7%.
Discussion
In the present study we found that HIV-1 drug resistance testing on DBS was feasible and reliable in a routine clinical setting in rural Tanzania. Genotyping was successful in 94% of DBS specimens, and there was a high concordance between mutations found in plasma and DBS. The use of DBS for genotypic resistance testing has previously been studied in well-resourced laboratories in Europe and North America, with amplification success rates ranging from 78.8-95.0% [11] [12] [13] [14] [15] 17] . Our study, however, is the first to report the successful use of this method under field conditions in a routine African ART programme, the setting where it can be of most use. One of the most important challenges with the use of DBS is to ensure sample preservation in the field. Several studies have investigated how storage conditions influence the ability to genotype HIV-1 from DBS. Youngpairoj et al. [15] found that 95% of DBS specimens could be genotyped after storage at 4°C for 1 year, whereas Ziemniak et al. [26] successfully genotyped all 16 viraemic DBS specimens stored at room temperature for up to 4.9 months. By contrast, two recent studies found that storage at extreme conditions (37°C and high humidity) had already severely compromised amplification after 2 weeks [16, 17] . The WHO, in collaboration with a network of international experts (HIVResNet), recently published a laboratory strategy for surveillance of transmitted HIV drug resistance, where the use of DBS was recommended in resource-limited settings [27] . Herein, it is recommended to store DBS at room temperature for a maximum period of 2 weeks before transport to the Discordances between plasma and dried blood spots (DBS) that represent drug-resistant mutations are in italic font and underlined. Discordances caused by mixtures with the wild-type strain are underlined. None had clinically relevant mutations in the protease gene.
a A comparison of viral load results in plasma and DBS has been published previously [33] . Table 2 . Reverse transcriptase mutations in plasma and dried blood spots from 36 patients with treatment failure HIV-1 resistance testing on DBS reference laboratory. In our study, however, storage at tropical room temperature for up to 3 months did not seem to impair amplification from DBS. More research is warranted to define user-friendly standard operating procedures for storage and shipment of DBS under diverse environmental conditions. The two DBS specimens that could not be amplified in our study both had low-level viraemia (<3,000 copies/ml). A reduced sensitivity when viral burden is low has also been observed by others, probably because of the small amount of blood present in DBS. Hallack et al. [14] found that 90% of DBS with a viral load ≥6,000 copies/ml were successfully genotyped, compared with 58% of DBS with a viral load <6,000 copies/ ml, using the Trugene HIV-1 Genotyping Kit (Siemens Medical Solutions Diagnostics, Tarrytown, NY, USA). Another study by Youngpairoj et al. [15] reported that only 8% of DBS could be genotyped when viral load was <10,000 copies/ml, compared with 81% when viral load was ≥10,000 copies/ml, using the commercial ViroSeq™ kit. In the latter study, however, the DBS were retested with an in-house RT-nested PCR assay, which successfully genotyped 95% of the samples. In the present study, we used an in-house RT-nested PCR method for amplification and the ViroSeq™ kit for sequencing, and achieved 88% amplification success even in DBS with low viral loads (<10,000 copies/ml). Thus, although commercial kits are efficacious in samples with high-level viraemia, such as untreated individuals, in-house RT-nested PCR assays appear to be more sensitive in samples with low-level viraemia.
Another challenge with the use of DBS is the potential contribution of HIV-1 proviral DNA from peripheral blood mononuclear cells (PBMC). Previous studies have demonstrated the presence of proviral DNA in 33-80% of RT-PCR-positive DBS, both from untreated and treated individuals [11] [12] [13] 17, 26] . Despite the presence of proviral DNA, however, these studies reported a high concordance between plasma-derived and DBS-derived sequences, which is in agreement with our results. The interference of proviral DNA might vary according to treatment status and viral load level, and in patients who fail treatment, more drug-resistant mutations tend to be detectable in plasma than in PBMC, particularly when viral burden is low [28, 29] . In our study, 4 of the 6 drug-resistant mutations that were missed in DBS were from patients with low-level viraemia (≤3,000 copies/ ml), which could be explained by the relatively larger contribution of proviral DNA to the DBS-derived genotype in these patients. By contrast, in patients who interrupt treatment, proviral DNA in PBMC can act as an archive of resistance mutations, and DBS might provide more information than plasma in such patients [29] . However, this was not observed in patients who interrupted treatment in our study, possibly because of a high HIV-1 RNA viral load outnumbering the contribution from proviral DNA. The relevance of treatment status and viral load level when DBS are used to genotype HIV-1 deserves further investigation.
Monitoring of ART with viral loads and genotypic resistance testing is considered standard of care in highincome countries, in order to detect treatment failure and to design effective second-line regimens [5] . Up to now, however, these tests have been largely unavailable to patients in resource-limited settings. As more and more people are receiving ART in low-and middleincome countries, the need for virological monitoring in clinical care can be expected to increase greatly in the coming years [1, 30] . Several studies have demonstrated that DBS can be used to reliably quantify HIV-1 RNA [9, 31, 32] , even under field conditions [10, 33, 34] . Furthermore, with an increasing body of evidence to support resistance testing on DBS, including the present study, virological monitoring in resource-limited settings could now be within reach [11] [12] [13] [14] [15] 17] . DBS specimens could be obtained even in remote clinics with limited laboratory facilities and shipped to a central laboratory for investigation, either as a routine test at set time points, or in selected patients with suspected treatment failure. Each filter paper card contains four to five blood spots, of which two are needed to quantify HIV-1 RNA, and the remaining can be used for resistance testing in viraemic patients. Such a monitoring strategy would demand an upgrading and funding of central laboratories, but would be fully feasible, and should be considered in the next revision of the WHO guidelines for ART in resource-limited settings.
Our study was limited by a relatively small sample size, and a larger study would have given more precise estimates of DBS performance. Furthermore, as environmental conditions differ considerably between regions, the results reported here can not be generalized to all tropical climates. The main strength of our study was that we achieved excellent results by the use of a field-friendly protocol, with DBS storage and shipment at ambient temperature, and we believe our method would be feasible in other resource-limited settings.
In conclusion, we found that genotyping was successful in the vast majority of DBS specimens obtained under field conditions in rural Tanzania and stored at ambient temperature for up to 3 months. Furthermore, in clinical samples from patients who failed ART, there was a high concordance between resistance mutations detected in DBS and plasma, suggesting that DBS can be a feasible and reliable option for drug resistance monitoring of patients with treatment failure. The use of DBS can markedly improve access to drug resistance testing for HIV-1-infected individuals in resourcelimited settings, and might be considered for clinical use in such settings.
